All In MedTech

FDA Clearance Tracker · P100018

PIPELINE EMBOLIZATION DEVICE

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Apr 6, 2011 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Apr 6, 2011

Approved

Time to decision

323 days

Received May 18, 2010. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P100018
Device name
PIPELINE EMBOLIZATION DEVICE
Applicant location
Irvine, CA
Received
May 18, 2010
Decided
Apr 6, 2011
Decision
Approved
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
51 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code OUT

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE PIPELINE EMBOLIZATION DEVICE. THIS DEVICE IS INDICATED FOR THE ENDOVASCULAR TREATMENT OF ADULTS (AGE 22 AND ABOVE) WITH LARGE OR GIANT WIDE-NECKED INTRACRANIAL ANEURYSMS IN THE INTERNAL CAROTID ARTERY FROM THE PETROUS TO THE SUPERIOR HYPOPHYSEAL SEGMENTS.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code OUT (Intracranial aneurysm flow diverter).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Micro Therapeutics, Inc. d/b/a ev3 Neurovascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.